Novel drug therapy targets aggressive form of non-hodgkin's lymphoma
Monday, December 10, 2012 - 20:30
in Health & Medicine
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell – DLBCL (ABC-DLBCL), remains a major therapeutic challenge. Researchers have now developed a new experimental drug therapy to target this aggressive form of lymphoma.